Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.

Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.

File Thomas M Jr; Mandell Lionel A; Tillotson Glenn; Kostov Kosta; Georgiev Ognian

The Journal of antimicrobial chemotherapy

2007

2007-07

OBJECTIVES: Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP. PATIENTS AND METHODS: In a multicentre, double-blind, parallel group study, patients were randomized to receive 320 mg of oral gemifloxacin once daily for 5 or 7 days. Over 95% of all patients in each cohort had a Fine score of

80 and over; Adolescent; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/adverse effects/therapeutic use; Bacterial/*drug therapy/microbiology; Community-Acquired Infections/*drug therapy/microbiology; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones/*administration & dosage/adverse effects/therapeutic use; Gemifloxacin; Humans; Male; Middle Aged; Naphthyridines/*administration & dosage/adverse effects/therapeutic use; Pneumococcal/drug therapy/microbiology; Pneumonia; Streptococcus pneumoniae/isolation & purification; Treatment Outcome

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

112–120

1

60